Printer Friendly

Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system.

1. Background

Chemokines (CKs) are low molecular weight chemoattractant peptides, belonging to the cytokine family [1]. Differently from interleukins, CKs act via G protein-coupled receptors (GPCRs), controlling cell migration and trafficking throughout the body, during immune response [2] and development [3,4]. CKs are also critical mediators of several physiological mechanisms such as wound-healing and tissue homeostasis [3, 5]; moreover, CKs are expressed in the central nervous system (CNS) [6, 7] where they not only act as mediators of development, intercellular communication, and inflammatory processes but also function as neurotransmitters or neuromodulators, mainly involved in neuroendocrine regulations [8]. Recently, it has been shown that CKs play a relevant role in tumorigenesis, neoangiogenesis, tumor progression, and metastasization [9,10]. Evidence for autocrine/paracrine regulatory mechanisms in different normal and cancer cell types, driven by chemokine/receptors interaction on the same or a nearby cell, supports the potential role of CKs in the control of physiological or tumoral endocrine functions. In particular, the chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptors, CXCR4 and CXCR7, have been involved in cancer cell proliferation, migration, and invasion [11-13].

Anterior pituitary adenomas account for approximately 15% of primary intracranial tumors. They are classified by size (microadenoma, <10 mm or macroadenoma, >10 mm) and on the basis of their ability to produce hormones, as secreting or functioning tumors (about 50% of adenomas) or as clinically nonfunctioning pituitary adenomas (NFPA) that do not release hormones or, more often, secrete clinically nonrelevant (i.e., gonadotropins) or nonbioactive hormones ([alpha]-subunit of glycoproteic hormones) [14, 15]. Almost all pituitary tumors display a benign clinical course being slow growing and show low incidence of metastasis; however, they are frequently associated with high morbidity and mortality due to mass-related effects and paraneoplastic syndromes related to hormone hypersecretion. Functioning pituitary adenoma leads to hypersecretion of hormones that results in classic clinical syndromes, mainly acromegaly (overproduction of GH), hyperprolactinemia (excess of PRL), and Cushing's disease (overproduction of ACTH) and, more rarely, secondary hyperthyroidism (increased TSH secretion). These tumors can be monohormonal or plurihormonal. NFPAs do not secrete sufficient hormones (mainly FSH or LH) to be detectable in the blood or to cause hormonal manifestations; in other cases only biologically inactive [alpha]-subunit is released and more rarely they are classified as true nonsecreting adenomas. Importantly, all pituitary adenomas may induce hypopituitarism and neurological symptoms (for example compression of the optic chiasma) due to mass effect [16,17]. Clinical relevance and recent advances in the comprehension of their molecular pathogenesis suggest that pituitary adenomas should be considered a more critical disease than a benign endocrine pathology. Thus, a deeper evaluation of the mechanisms at the basis of their tumorigenesis and better prognostic markers to identify tumors with a high risk of recurrence are most awaited to improve pituitary adenoma clinical outcome.

This review will focus on the diverse role of CXC chemokines and their receptors in normal pituitary cell functions and pituitary tumor development and progression, summarize recent progress in CXCR7 functions, and discuss the present issues and future perspectives.

2. Chemokine Classification and Receptor Interactions

Human CK system includes approximately 50 peptides and 22 GPCRs. CKs are classified, according to the number and spacing of the first two cysteine residues of a conserved cysteine motif, into four groups: (1) CXC (with a single nonconserved amino acid residue -X- between the first N-terminal C residues: CXCL1-17); (2) CC (two adjacent cysteine residues: CCL1-28); (3) XC (only one N-terminal cysteine: XCL1-2); (4) CX3C (three nonconserved amino acid residues separating the N-terminal C residues: CX3CL1) [18, 19].

CK receptors are typical GPCRs, all of them signaling through heterotrimeric G proteins (Ga, and G[beta]-[gamma] subunits), with the remarkable exception of CXCR7 which is exclusively biased towards [beta]-arrestin-mediated signaling [20]. Upon ligand binding, many CK receptors may form homo- and heterodimers that activate distinct intracellular signaling pathways from individual receptors [21]. The classification of CK receptors is based on the class of their ligands (e.g., CXC ligands bind CXC receptors).

CKs may also bind a small group of so-called "atypical chemokine receptors" (ACKRs), which are unable to initiate downstream conventional G-protein-dependent signaling, resulting, from a functional point of view, in the inability to induce directional cell migration [22]. These receptors bind distinct and complementary range of CKs and likely control CK networks during development and physiopathological processes by scavenging CKs. ACKRs, including Duffy antigen receptor for chemokines (DARC, ACKR1), C6 (ACKR2), CXCR7 (ACKR3), and CCX-CKR1 (ACKR4) (for classification and nomenclature see [23]), were proposed to serve as decoy receptors to scavenge inflammatory CKs from the extracellular microenvironment, inhibiting their signaling [22]. Indeed, recent evidence supports the ability of ACKRs to transport, internalize, and degrade CKs, leading to the formation of CK gradients in normal and cancer tissues, responsible for the functional modulation of their signaling.

CKs belonging to the CXC family can be further grouped according to the presence or absence of a the tripeptide motif Glu-Leu-Arg (eLr) preceding the CXC domain ([ELR.sup.+] or [ELR.sup.-]), which affects receptor binding specificity and biological effects. Notably, [ELR.sup.-] CXC chemokines (i.e., CXCL9, -10 and -11) are interferon [gamma]-inducible and act as potent angiostatic factors to impair angiogenic stimuli induced by growth factors. Conversely, [ELR.sup.+] CKs (CXCL1, -2, -3, -5, -6, -7, -8) are proangiogenic [24,25]. CXCL12 (previously known as stromal cell-derived factor-1, SDF-1) is an exception to this characterization, since it is [ELR.sup.-] but mediates tumor-promoting angiogenesis via its receptor CXCR4 [9, 24, 26].

Common features shared by all CKs are pleiotropism, promiscuity, and redundancy, with a single CK able to bind several receptors, whereas multiple CKs bind the same receptor resulting in the same functional outcome 27].

Upon ligand binding, CK receptors undergo conformational change that activates the G[alpha] subunits sensitive to Bordetella pertussis toxin (PTX). Their activation dissociates the GTP-bound G[alpha] subunit from the G[beta]-[gamma] dimer, and both these active components trigger intracellular signals, such as activation of phospholipase C (PLC)/inositol triphosphate (IP3)-[Ca.sup.2+]/diacyl glycerol (DAG)/protein kinase C (PKC) and inhibition of adenylyl cyclase (AC)-cAMP/protein kinase A (PKA). Moreover, these receptors control the activity of different kinases, including extracellular regulated kinases (ERK1/2), c-Jun N-terminal kinase (JNK), p38, phosphatidyl inositol 3 kinase (PI3K)-Akt, and the focal adhesion kinase (FAK).

The distinct transductional cascades regulated by CK receptors mainly depend on the G[alpha] subfamily which they activate: G[alpha]i inhibits AC but also activates tyrosine kinases of the Src family, favoring signal integration; G[alpha]q increases PLC[beta] activity [12], to cleave PIP2 to form DAG and IP3. In turn, DAG activates PKC, whereas IP3 binds specific receptors on the endoplasmic reticulum inducing [Ca.sup.2+] release from intracellular stores. Finally, G[alpha]12 controls the activity of the small G protein RhoA, via Rho-GEF. On the other hand, CK receptor activation of G[beta][gamma] subunits results in the activation of PI3K leading, through the phosphoinositide-dependent kinase 1 and 2 (PDK1-2), to Akt phosphorylation and subsequent activation of its downstream signal proteins such as glycogen synthase kinase 3 (GSK3), mammalian target of rapamycin (mTOR), and FAK, which control migration in different types of normal and tumor cells [28].

After stimulatory responses, the inactivation of CK receptor signaling occurs after the hydrolysis of GTP to GDP by the intrinsic GTPase activity of G[alpha] subunit, followed by its reassociation with G[beta]/[gamma] in an inactive complex. Moreover, receptor desensitization, internalization, and lysosomal degradation are mediated by G protein-coupled receptor kinases (GRKs) and arrestins [29].

3. Physiological Functions of CKs: Focus on the CXCL12/CXCR4-R7 Axis in the CNS

CKs are constitutively secreted by leukocytes, fibroblasts, endothelial, and epithelial cells to mediate cell activation, trafficking, and homing [5, 30]. Beside their basal expression, most CKs are highly induced during inflammatory or infective processes driving different phases of immune response via a CK gradient which directs leukocyte recruitment to the site of inflammation. Furthermore, CKs directly activate specialized effector lymphocytes during the different steps of immune response, for example, CXCL8 (formerly named IL8) recruits neutrophils, basophils, and eosinophils expressing its receptors, CXCR1 and CXCR2 [2]. Adaptive immune responses are mediated by CKs (CXCL9-L10-L11) secreted by macrophages activated by INF-[gamma] released by natural killer and T helper 1 (Th1) cells that express CXCR3, the receptor for CXCL9-L11 [31], thus amplifying leukocyte recruitment and, finally, inflammation.

CKs also play a key role in embryogenesis, organogenesis, angiogenesis, and germ cell migration, especially during neural development [5]. The constitutive expression of CKs and their receptors in adult normal brain was initially identified in the immune-like competent cell populations such as microglia and astrocytes. The subsequent detection of their expression in neurons [32-34] broadened CK role as neuromodulators/neurotransmitters in neurological processes such as thermoregulation, pain perception, and stress conditions, as well as in pituitary functions.

Focusing on the CxCl12/cXcR4-R7 network, it exerts a variety of functions in CNS development as well as in mature brain. CXCL12 directs the migration of embryonic and adult stem cells in the developing central and peripheral nervous system [35,36], controlling the formation of cerebellum, cerebral cortex, hippocampus, and dorsal root and sympathetic ganglia [25, 37, 38]. Postnatally, CXCR4 expression, while downregulated in many brain areas, persists in the hypothalamus where it modulates the hypothalamic-pituitary system and the hypothalamic-pituitary-gonadal axis, in particular, cooperating to the regulation of neuroendocrine and reproductive systems [39-41].

As far as CNS development is concerned, the pivotal role of CXCL12/CXCR4 emerged from studies using knockout mice for either the ligand or the receptor. Both models exhibited a superimposable abnormal neuron migration in the cerebellum, dentate gyrus, and dorsal root ganglia [35, 36, 42, 43]. Furthermore, CXCL12/CXCR4 axis controls migration and homing of Cajal-Retzius cells [44, 45], post-mitotic neurons [46], cortical interneurons [40, 47-49], and dopaminergic neurons [50]. CXCL12/CXCR4 regulation of stem cell positioning and migration persists in adults, in the neurogenic niches of brain and in the bone marrow, where hematopoietic progenitors cells are retained by the interaction between ligand and receptor [51] that also promotes their survival and proliferation. Interestingly, a similar homing mechanism has been demonstrated for adult neural progenitor cells (NPCs) or neural stem cells (NSCs) [25].

CXCR7, the second CXCL12 receptor, has a 10-fold higher binding affinity than CXCR4 but also binds CXCL11 (formerly known as IFN-inducible T cell a chemoattractant, I-TAC,), which, in turn, interacts with CXCR3 [52]. Presently, the function of CXCR7 is still controversial [53]. CXCR7 does not mediate CXCL12-dependent cell migration [20, 52, 54] and displays atypical signaling pathways, failing to induce intracellular [Ca.sup.2+] mobilization and inhibition of cAMP production, since this receptor does not seem to be coupled to Gia. Based on its ability to rapidly sequester and degrade CXCL12 and thus to suppress CXCR4 activity, CXCR7 was firstly proposed to be a decoy receptor [54-57]; currently, this activity is considered only a part of the possible mechanisms by which CXCR7 modulates cellular functions [22]. Indeed, emerging evidence suggests that CXCR7 can promote cell motility [58-60] and trigger intracellular signals in different human normal and cancer cell types [61-64]. In particular, CXCR7 activates Akt, MAP kinase (MAPK), and JAK/STAT3 cascades, either by direct modulation, through a [beta]-arrestin-dependent pathway [20, 65], or after heterodimerization with CXCR4 [59, 66-69]. Preferential signaling through G-proteins or [beta]-arrestin is influenced by both CXCR4-CXCR7 dimer formation and the oligomerization state of CXCL12 [70, 71]. CXCR7 was recently shown to activate mTOR in human renal cancer cells through the modulation of ERK1/2 and p38 activities [72], further suggesting that it is a fully signaling receptor although independent from G proteins. However, CXCR7 knockout mice display a lethal phenotype due to a heart valve and vascular defects [73], a very similar scenario observed in mice with targeted disruption of the genes encoding CXCR4 and CXCL12 [67, 74].

In the adult rat brain, CXCR7 is expressed at high levels in vessels, pyramidal cells, and mature dentate gyrus granule cells, overlapping CXCL12 expression pattern [75, 76], and a functional role for CXCR7 in the control of neuronal migration to the subventricular and intermediate zone was suggested [69,77]. In rat mature neurons and blood vessels, CXCR7 appears to be the preponderant CXCL12 receptor, likely contributing to CXCL12-dependent neuronal development [75]. Moreover, CXCR7 acts as scavenger on brain microvessel endothelium [78] and it is essential for inflammatory leukocytes to infiltrate the CNS [79]. CXCR7 is also expressed in neural tube and brain of mice embryos. In rat cortex, CXCR7 is localized in GABAergic neuron precursors, and Cajal-Retzius cells and, unlike CXCR4, it has been identified in neurons forming the cortical plate and in the developing dentate gyrus and cerebellar external germinal layer [75, 80].

Migrating immature cortical interneurons co-express CXCR4 (membrane surface expression) and CXCR7 (intracellular expression, mainly endosomes) [77]. CXCR7 rapidly recycles from membrane to intracellular pools of interneurons, and its trafficking mediates CXCL12 endocytosis. It is essential for the regulation of interneuron migration in the developing cerebral cortex since its removal causes an increase in extracellular CXCL12 content, which favors its binding to CXCR4 and consequently induces the endocytosis and degradation of CXCR4. Thus, CXCR7 regulates CXCR4 expression and likely controls CXCL12 signaling to drive successful migration in the developing cerebral cortex [77]. In addition, since [CXCR7.sup.-/-] and [CXCR4.sup.-/-] mutant mice displayed opposite defects in interneuron motility and positioning, CXCR4 and CXCR7 were proposed to have distinct roles and signal transduction to regulate interneuron movement [69]. This fine tuning of CXCL12 response induced by CXCR7 occurs either directly modulating [beta]-arrestin-mediated signaling cascades or scavenging local CXCL12 availability [81].

Deletion of one of the CXCL12 receptors is sufficient to generate a migration phenotype that corresponds to the CXCL12-deficient pathway and interfering with the CXCL12-scavenging activity of CXCR7 causes loss of CXCR4 function [81]. For example, during development, CXCL12 regulates the migration of gonadotropin-releasing hormone (GnRH) neurons, through CXCR4-mediated activation of the GIRK channel [82], but this effect is modulated by CXCR7 which controls CXCL12 content availability acting as a scavenger along the migratory path [83].

The relevance of CXCL12 and CXCR4-R7 system in CNS ontogeny and functions is even more crucial in the view of their expression in both embryonic and adult brain stem cells, a subset of undifferentiated cells characterized by selfrenewal through asymmetric division, differentiation into multiple lineages, and constant proliferation that in adults acts in tissue maintenance and repair [84]. The role of CXCL12 and CXCR4 in stemness maintenance has gained much attention also in the neuroendocrinology field due to the proposed role of stem cells in pituitary plasticity 84, 85]. Both CXCL12 and CXCR4 are expressed in different anterior pituitary cell subtypes, as well as in nonhormonal cell types [86-88]. The chemotactic activity of this CK could be also relevant in folliculostellate (FS) cell, non-FS nestin+ cell, and stem cell migration [86, 89]. Therefore, understanding the CK-dependent mechanisms associated with candidate stem cells within pituitary might help to clarify their activity in development or in normal mature hormone-producing and tumor pituitary cells [84, 90, 91].

The stem cell concept applied to cancer has radically changed the research approach to tumorigenesis and treatment, since the subset of cancer cells, namely, cancer stem cells (CSCs), seems responsible for tumor initiation, metastasis, and resistance to therapy [92]. Although, at present, all factors and signals that regulate CSCs are not completely clarified, accumulating evidence suggests a key role of the CXCL12/CXCR4 axis in CSC maintenance and growth [62, 93]. Moreover, interactions between CSCs and tumor microenvironment through secreted CKs (e.g., CXCL12) [13], possibly occurring also in pituitary adenomas, may act as chemoattractant to recruit fibroblasts, endothelial, mesenchymal, and inflammatory cells to the tumor, via CXCR4.

4. Chemokine Functions in Normal Pituitary

Through the release of growth factors (bFGF, EGF, and VEGF), cyto/chemokines, and neuroendocrine proteins (steroid hormones, prolactin, growth hormone, ghrelin, erythropoietin, catecholamines, etc.) neuronal and neuroendocrine pathways regulate fundamental functions within the CNS and its interaction with the immune system [94]. Complex autocrine/paracrine signals through neuropeptides (e.g., EGF and VIP), neurotransmitters, cytokines (IL-1, IL-6), and CKs occur also in pituitary regulation, differently from the classical hypothalamic input and feedback signals from the periphery [95-97].

EGF expression has been observed at all stages of pituitary development and in the adult pituitary, and the EGFR pathway contributes to pituitary physiology and tumorigenesis [98].

IL-1[beta] receptors were detected in pituitary cells [99], and their activation inhibits prolactin (PRL) secretion from dispersed rat pituitary cells through the regulation of AC and PLC activities, and [Ca.sup.2+] fluxes [100-103].

IL-6 and its receptors are also expressed in the pituitary gland [104, 105] where their interaction regulates apoptosis and proliferation of endocrine cells in vitro [106]. IL-6 is mainly produced by the FS cells and activates a paracrine loop on the hormone-secreting cells [107, 108] regulating ACTH [109], PRL, LH, and GH secretion [110-112] via the modulation of AC and PLC activities [113]. Interestingly, IL-6 exerts opposite effects on normal and adenomatous pituitary cells: it is inhibitory for normal anterior pituitary [114] and stimulatory for adenoma cells [107].

IL-18 was also proposed to exert paracrine effects in pig anterior pituitary being the ligand and its receptor expressed by different subsets of GH secreting cells [115].

Finally, interleukins' regulation of the hypothalamic-pituitary-adrenal axis also involves the modulation ofvasoactive intestinal peptide- (VIP-) secreting pituitary cells to control, in a paracrine manner, PRL release [116].

More recently, several studies were directed on the role of CKs in pituitary. CKs can affect pituitary hormone secretion via the hypothalamic-pituitary axis or autocrine/paracrine regulation. CXCL1 is expressed in the posterior pituitary, in the paraventricular nucleus (PVN) of the hypothalamus and the median eminence [6]. In response to stressful stimuli, this CK is released in the median eminence [117] to reach its receptor (CXCR2) expressed in pituitary cells and induce the release of PRL and GH and the inhibition of LH and FSH secretion [118]. Similarly, CCL2 was identified in both hypothalamus and pituitary [119]. The generation of transgenic rats (S100[beta]-GFP rats) that express green fluorescent protein in S100[beta]-positive pituitary FS cells in the anterior pituitary [120] led to the characterization of S100[beta]-positive cells [86, 121] and transcripts of CXCL10 (IFN-[gamma] inducible protein 10 kDa, IP-10) were identified in a subpopulation of these cells. Importantly, CXCR3, the receptor for CXCL10, was shown to be expressed in corticotrophs, suggesting a possible autocrine/paracrine effect of CXCL10, released from FS cells, on ACTH-producing cells [122].

CXCL12/CXCR4 is the major regulatory axis not only connecting the immune and nervous systems, but also playing a role in neuroimmune regulation of the anterior pituitary physiological functions [6].

CXCL12 was detected in both rat pituitary [123] and hypothalamus [124] and its expression in hypothalamic neurons, concomitant with CXCR4 positivity at pituitary level [124], corroborated the hypothesis that this CK could represent a hypothalamic regulatory factor of anterior pituitary function. As a consequence, the chemokinergic regulation of anterior pituitary cells might derive from coordinate activity of CXCL12 originating from both hypothalamic neurons and systemic circulation [95]. A regionalized constitutive expression of CXCL12 was reported in adult rat brain, particularly in arginine vasopressin- (AVP-) expressing neurons [125] where its interaction with CXCR4 leads to modulates induced plasma AVP release in vivo [39]. The expression pattern of this chemokine and its receptor in the rat hypothalamo-neurohypophyseal system was further investigated: they colocalize within AVP-expressing neurons in both supraoptic (SON) and paraventricular (PVN) nucleus as well as in dense core vesicles of AVP-positive nerve terminals in the posterior pituitary, showing a similar distribution [126]. Since AVP controls body fluid homeostasis, the interaction between CXCL12 and AVP was studied in AVP-deficient Brattleboro rats that show low expression of both CXCL12 and CXCR4, correlated with aVp protein expression level in SON, PVN, and posterior pituitary. However, since CXCL12 mRNA is increased, it was hypothesized that CXCL12 synthesis is present in these cells but, being costored with AVP, a concomitant massive release of both peptides is responsible for their low content at both hypothalamic and posterior pituitary levels [126]. AVP and CXCL12 expression is dependent on water balance and is centrally regulated, further strengthening the role of CXCL12 in neuroendocrine functions. However, CXCL12 and CXCR4 are also coexpressed in rat pituitary cells [127] and a further autocrine/paracrine regulation of pituitary functioning was hypothesized. Complete colocalization between CXCR4 and GH was reported in normal rat pituitary, suggesting that CXCR4 is a rather specific regulator of somatotroph activity, in rats [128]. Indeed, CXCL12 stimulates GH transcription and secretion in both primary rat anterior pituitary cells and the GH-producing pituitary adenoma cell line, GH3 [128]. Interestingly, rat FS cells also express CXCR4 and secrete CXCL12, which acts as a potent chemoattractant for these cells. The activation of this autocrine loop facilitates the formation of F-actin in FS cells and the subsequent directional extension of their cytoplasmic processes toward other FS cells [86]. CXCL12/CXCR4 interaction induces invasion and interconnection of FS cells to near lobular structures likely forming a circuit that causes or maintains local cellular arrangement in the anterior pituitary [86].

In humans, a slightly different pattern of expression was found in autoptic normal pituitaries. Scattered expression of both CXCR4 and CXCL12 within the anterior lobe was detected by immunohistochemistry, revealing a nonhomogeneous positivity for both proteins throughout the tissue, including large negative areas, others showing few positive cells and rare zones with higher expression [129] (Figure 1). Interestingly, in all these areas, CXCR4 expression resulted largely higher than its ligand, although all the CXCL12positive cells express CXCR4, as well. CXCR4-expressing cells do not belong to specific secreting cell type, being present in GH, PRL, or ACTH-secreting cells, while no expression was observed in human FS cells. However, some CXCR4expressing cells do not coexpress any hormones and no colocalization of either CXCR4 or CXCL12 was observed in FS cells; thus it was proposed that CXCL12/CXCR4 system may also label undifferentiated/progenitor cells. Conversely, the rare CXCL12-positive cells were mainly, although not exclusively, corticotrophs [129]. Notably, this CK-receptor pair was undetectable in human posterior pituitary lobe [129], contrarily to what was observed in rats. Thus, from these data it is evident that, in normal pituitary, CXCL12 is secreted by cell subpopulations that, cooperating with hypothalamic factors (including CXCL12 itself), may contribute to paracrine modulation of pituitary functioning (Figure 2). Consequently, alterations ofthe endocrine regulatory pathways due to upregulation of hypothalamic/pituitary CXCL12/CXCR4 axis might lead to the development of pituitary adenomas [127,129].

The activity of CXCR7 in normal pituitary deserves further investigation; however its expression in pituitary adenoma tissues [130, 131] suggests possible involvement in pituitary function regulation.

5. CXCL12/CXCR4-R7 in Cancer Development and Progression: Autocrine/Paracrine Loops

Beside direct CXCR4-dependent activation of ERK1/2, transactivation of tyrosine kinase receptors is currently a relevant mechanism in tumor cell responses. Mainly, the transactivation of epidermal growth factor receptor (EGFR) family members mediates the mitogenic activity of different CKs in human cancer. A cross-talk between CXCL12 and EGFR and/or HER2/neu phosphorylation was demonstrated in breast and ovarian cancer cells through G protein-dependent activation of kinases of the Src family [132-134]. Moreover, in breast cancer, CXCR4 interacts with the EGFR variant, EGFR vIII, a constitutively active mutant highly expressed in cancer stem cells [135], to regulate invasion via p38 MAPK [136]. CXCR4 signaling is negatively regulated by protein-tyrosine phosphatases (PTPs), such as the Src homology-containing protein-tyrosine phosphatase 1 (SHP1) and the SH2 domain-containing inositol 5-phosphatases (SHIP), while SHP2, constitutively associated with CXCR4, potentiates CK signaling [137, 138]. These observations are particularly relevant since they highlight possible direct antagonisms between CXCR4 and somatostatin receptors (SSTR) that are powerful activators of PTPs [139-141]. This antagonistic activity could acquire clinical relevance in light of the fact that SSTR agonists are the main pharmacological tool available for the treatment of pituitary adenomas [142, 143].

The concomitant expression of ligand-receptor pair in the same tumor cells, responsible of autocrine/paracrine activation, is one of the leading causes of clinical aggressive behavior in various cancer types [144, 145]. Exploiting the coexpression of CKs and their receptors, cancer cells and cells of the tumor microenvironment are able to modulate immune response, promote angiogenesis, and sustain proliferation [146]. As previously described, this autocrine mechanism is maximally effective for CXCR4, the most widely expressed CK receptor in human solid and hemopoietic malignancies [28]. The autocrine/paracrine loop of the CXCL12/CXCR4 pair has been deeply investigated in brain tumors in both in vitro and in vivo models: CXCL12 stimulates proliferation and migration of glioblastoma cells and xenografted tumors inducing ERK1/2 and Akt phosphorylation [147-149]. The mitogenic activity mediated by CXCL12CXCR4 was also reported in meningioma, in which CXCR4 activation increased DNA synthesis through activation of ERK1/2 in primary cultures and its expression level significantly correlated with Ki-67 proliferation index of the original tumor tissue [150,151], while CXCR7 was mainly localized in tumor endothelia [152].

Similar CXCR4 tumor-promoting effects were observed in breast carcinoma [80], suggesting CXCL12 as possible autocrine/paracrine growth factor [153]. Interestingly, in breast cancer cells the synthesis and release of CXCL12 is under the control of 17[beta]-estradiol contributing to its proliferative effects and mediating, via a Src-dependent mechanism, EGFR transactivation [133,154].

Furthermore, CXCL12 is also indirectly implicated in tumor pathogenesis, acting as chemoattractant for CXCR4-positive cells, directing tumor cell migration [155-157] and controlling invasive and metastatic properties of CXCR4expressing cancer cells to distant organs [158, 159]. The invasive behavior of cancer cells might indirectly depend on locally released CXCL2 that, via an autocrine mechanism, binds to CXCR4 impairing chemotaxis towards CXCL12-producing target organs and metastatic spread [160]. In addition, normal cells forming tumor stroma (i.e., macrophages, lymphocytes, fibroblasts, and endothelial cells) concur to cancer development and progression through CXCL12 secretion. CXCL12 concentration gradient directs cancer cell motility in several tumors [10,161], including aggressive solid neoplasms (breast [153], colon [162],brain [149] ovarian 163], prostate [161], renal cell [164] and oral squamous cell [165] carcinomas, and melanoma [166]). Importantly, as observed in a rat mammary adenocarcinoma cell line overexpressing both receptors [167], CXCR4 and CXCR7 play opposing roles in breast cancer metastasis: CXCR4 mediates cancer cell invasion allowing cells to follow the CXCL12 gradient generated by metastatic targets whereas CXCR7 favors tumor growth increasing angiogenesis but impairs cell migration scavenging the chemokine.

6. A Network Map of Proliferative Signaling in Pituitary Tumor Development

Raf/MEK/ERK and PI3K/Akt pathway dysregulation is a common alteration responsible of tumor initiation and progression. While the pathways are classically activated by growth factors, cross-talks and transactivation mechanisms with neuropeptide-cytokine-CK/GPCRs have been increasingly recognized. This cross-talk activates ERK1/2, which is directly responsible for cell growth and differentiation, depending on the cellular context and represents one of the major proliferative pathways in cancer [168,169].

The overexpression or constitutive activation of receptors for growth factors, cytokines, and CKs potentiates the activation of Ras/Raf/MEK/ERK pathway also in pituitary adenoma [170]. MAPK phosphorylation is relevant in different pituitary cell types such as AtT20 cells, where it regulates CRH-induced POMC transcription [171], gonadotrophs for GnRH signaling [172], GH-secreting cells for GHRH-dependent cyclin D1 expression [169], and GH4C1 somatotroph cell line in which the Gsp oncogene impairs Ras/ERK1/2-dependent PRL gene regulation [173]. PI3K/AKT/mTOR pathway, activated by a variety of growth factors and hormones, when dysregulated, leads to aberrant growth of pituitary adenoma cells. Akt is overexpressed and hyperphosphorylated in NFPA [174], in a mouse model of TSH-oma [175], and in GH3 cells in which the inhibition of PI3K/Akt signaling by octreotide increases the expression of the tumor suppressor gene Zac1 [176,177].

Similarly to cell proliferation, survival mechanisms also sustain pituitary development and tumorigenesis: in particular the balance of pro- and antiapoptotic factors [178], physiologically contributing to normal pituitary cell plasticity, when unbalanced, favors pituitary cell transformation [179]. For example, in pituitary adenomas, antiapoptotic mediators, such as the bcl-2 protein family, are upregulated [180], while Fas, a major apoptotic factor in different cell types, activates apoptosis in both normal rat lactotrophs and somatotrophs [181] and in pituitary adenoma cell lines [182]. Several pituitary-related genes may exert a role in apoptosis of secretory pituitary cells, as the developmental factor PITX2 and the transcription factor Pit-1 [183, 184], although their mechanisms are not yet fully understood.

Recent studies, however, highlighted that, when considering the complexity of regulatory pathways involved in pituitary cell survival and proliferation, it should take into account not only apoptosis but also senescence, an alternative process acting during tumor-suppressive cell fate. Importantly, senescence is gaining biological significance also in pituitary adenomas, whose typical benign nature could result from protective antiproliferative mechanisms. Several transformation events (e.g., DNA damage, loss of tumor-suppressor gene, oncogene activation, and growth factor overexpression) induce preventive cellular senescence, characterized by cell cycle exit and subsequent irreversible proliferation arrest. Thus, pituitary tumors may be more prone to activate senescence-associated pathways, maintaining their benign behavior, preventing malignant transformation, and regulating their development [185]. Interestingly, IL-6 has been shown to participate in oncogene-induced senescence in pituitary gp130 overexpressing tumor cells [96]. Moreover, angiogenic and apoptotic processes cooperate in determining tumor aggressiveness, and this regulation might also be involved in the pathogenesis of pituitary transformation. The pituitary gland is highly vascularized but, unlike other solid malignancies, conflicting results are available on angiogenic factors associated with pituitary adenoma progression and recurrence [186, 187]. VEGF was proposed as pituitary proangiogenic factor and possible therapeutic target [188], and the hypoxia-inducible factor- (HIF-) a, a key molecule in hypoxic pathways triggering vessel formation, was detected in pituitary tumor tissues [189, 190] and may favor hemorrhage in pituitary macroadenomas [191].

CKs, particularly CXCL12 signaling via CXCR4 and CXCR7, represent candidate mediators of the above described intracellular pathways, determining proliferative, antiapoptotic, and angiogenic signals, thus possibly concurring to pituitary tumor development and aggressiveness.

7. Chemokines in Pituitary Tumorigenesis

Pituitary adenomas are common intracranial tumors of the adenohypophysis causing serious morbidity, due to excessive hormonal secretion, mass effects, and local invasion of surrounding structures. At present, the understanding of biological and molecular pathogenesis and mechanisms of progression of these tumors is largely incomplete (for review see [14, 192, 193]). Emerging evidence reports that multiple factors might contribute to pituitary tumorigenesis, such as frequently altered gene expression, genetic (aryl hydrocarbon receptor interacting protein, AIP [194]; multiple endocrine neoplasia syndrome type 1, MEN1 [195]; guanine nucleotide-activating alpha subunit, GNAS, [196]), and epigenetic (cyclin-dependent kinase inhibitor 2A, CDKN2A, or P16; FGFR2/melanoma associated antigen -MAGE-3 pathway) [197] mutations, and abnormal microRNAs [198].

The improvement of this knowledge is even more helpful taking into account the peculiar properties of pituitary adenomas as compared to other malignancies: they commonly grow slowly but with local invasive behavior and occasionally develop into high aggressive tumors. This often prevents the efficacy of surgical and systemic medical treatments, the latter hampered by the lack of definite mechanisms underlying pituitary cell transformation and potential therapeutic targets.

The role of CKs in pituitary tumor development has been scantily investigated. However, few studies addressed the potential role of components of this peptide family in regulating human pituitary tumorigenesis.

CXCL8 mRNA was identified in a small percentage of anterior pituitary adenomas [199, 200], altogether with the expression of CXCR2 [201], the CXCL8 receptor that also binds other CXC CKs (CXCL1, CXCL7), confirming the potentiality of autocrine stimulation in pituitary adenomas. Indeed, a consistent release of CXCL8 was observed in primary cultures derived from human somatotroph adenomas, induced by stimulation with interleukin-1[beta] and inhibited by GH releasing hormone (GHRH) [202]. Thus, a further assessment of the possible role of this CK in the pathogenesis of pituitary tumors is required, likely being based on CXCL8 ability to recruit active neutrophil within the adenoma, influencing the inflammatory response or acting as mitogen for normal and transformed cells.

However, the majority of studies focused on the analysis of CXCL12 and CXCR4 expression in human neoplastic pituitary tissues and their role in adenoma cell proliferation [128,129, 203-205].

CXCR4 mRNA is expressed in almost all GH-secreting pituitary adenomas and in the great majority of NFPAs, whilst CXCL12 was identified in about 2/3 of these tumors. Notably, most CXCL12-positive cells also express CXCR4 strongly suggesting an autocrine/paracrine regulation of tumor cell proliferation [129, 205]. This hypothesis was further confirmed measuring the in vitro basal secretion of CXCL12 by human pituitary adenoma primary cultures resulting in an autocrine constitutive stimulation of DNA synthesis [129] (Figure 2) and, indirectly, by the absence of CXCR4 activating mutations in GH-secreting and NFPA able to sustain adenoma cell proliferation [204]. This observation was confirmed by a high percentage of different types of secreting pituitary adenomas showing expression of both CXCL12 and CXCR4 [129, 203, 204]. Finally, the evaluation of CXCR4 and CXCL12 expression in invasive and noninvasive pituitary adenoma specimens, by flow cytometry and immunohistochemical staining, demonstrated that the percentage of CXCR4- and CXCL12-positive cells was significantly higher in invasive pituitary adenomas [206]. Thus, the correlation of CXCR4 and CXCL12 expression levels and tumor invasiveness was proposed to be exploited as potential early diagnostic biomarkers, one of the major challenges in diagnosis and treatment of invasive tumors.

Among the mechanisms that occur in pituitary tumorigenesis, angiogenesis represents a key process for tumor growth. Interestingly, while controversial findings on the role of VEGF were reported [207-209], CXCL12 has been proposed as a better defined proangiogenic and proliferative factor in pituitary adenomas. In fact, CXCL12 and CXCR4 are concomitantly upregulated in hypoxic foci within pituitary tumor tissues, and one of the main CXCL12 effects in pituitary adenomas is to mobilize CD34- (and CXCR4-) expressing endothelial progenitors and promote their homing in ischemic foci activating the proangiogenic program [203]. Moreover, in GH3 rat pituitary adenoma cells, hypoxia-activated CXCL12-CXCR4 signaling interacts with the endocrine pathways resulting in upregulation of GH synthesis and secretion and cell proliferation [210]. Thus, in pathological conditions (i.e., hypoxia), on one hand, increased CXCL12 and CXCR4 expression and signalling may promote neoangiogenesis by recruiting endothelial progenitor cells and/or inducing proliferation of endothelial cells and, on the other, directly favouring hormone hypersecretion and pituitary cell proliferation.

Interestingly, GH4C1 rat pituitary adenoma cell line expresses CXCR4 but not CXCL12, thus it was proposed as a suitable model to characterize the molecular pathways regulated by this receptor in pituitary adenomas, without the interference of the endogenously released CK [127, 211, 212]. In these cells CXCL12 exerts a powerful secretagogue and mitogenic activity, as well as promotes cell migration [212]. Interestingly, these effects are induced by different and independent intracellular mechanisms, although all of them were PTX-dependent. GH secretion is a [Ca.sup.2+]-dependent event, in which increased ion concentration resulted from IP3-mediated [Ca.sup.2+] release from intracellular stores. Conversely, GH4C1 proliferation is induced by CXCL12 through the activation of ERK1/2 through the "classical" MEK-dependent pathway and via the activation of the cytosolic [Ca.sup.2+]-dependent tyrosine kinase, Pyk2, that, in turn, activates the large-conductance [Ca.sup.2+]-activated [K.sup.+] channels (BKCa) [95,127, 211, 212]. Similarly, CXCL12/CXCR4 modulation of ERK1/2 activity was reported in GH3 cells [128].

To date, the role of CXCL12/CXCR4 as potential pharmacological target in acromegalic patients has been scantily investigated. It was shown that a synthetic antagonist of CXCR4, d-Arg3FC131, is able to inhibit the growth of GH3 tumor cells and trigger apoptosis both in vitro and in mice xenografts [213]. Similar results were obtained using phidianidine A, an indole alkaloid isolated from the marine opisthobranch mollusc Phidiana militaris, which reduced GH4C1 proliferation, migration, and ERK1/2 phosphorylation [212].

CXCR7, the second CXCL12 receptor, was reported to be expressed in the AtT20 mouse corticotroph pituitary adenoma cell line [131], but the characterization of its possible role in pituitary adenoma development or progression will require further evaluation.

Studies on human pituitary adenoma cells derived from postsurgical specimens are limited, mostly due to their low proliferative activity in vitro. However, such generalized CXCR4 and CXCL12 overexpression in human pituitary adenomas, as compared to normal pituitary [129], strongly suggests that, in conditions of deregulation, this receptor system could be a relevant factor for pituitary adenoma development and/or progression. However, CXCL12 effects of on cell proliferation were directly evaluated in vitro on a small number of primary cultures of adenoma cell derived from GHoma, NFPA, and ACTH-secreting adenomas [129]. To avoid interference with the CXCL12 released from fibroblasts a specific protocol to obtain adenoma cell cultures highly purified [214] was used. CXCL12 induced a statistically significant increase in DNA synthesis in the majority (65%) of the adenoma tested. Interestingly, in few adenomas, the blockade of CXCR4 with AMD3100, a known CXCR4 antagonist, caused, beside the abolishment of CXCL12-mediated increase in cell proliferation, also a reduction of basal DNA synthesis. Measuring CXCL12 levels in the culture medium, it was shown that these tumors retained in vitro a significant basal secretion of CXCL12 causing a constitutive, autocrine stimulation of DNA synthesis [129]. Thus, these data suggest that pituitary adenoma cells over-express CXCL12 and CXCR4 as compared to normal tissue and that an autocrine activation of this pathway (Figure 2), actually, occurs in vivo.

Overall, these observations imply that CXCL12/CXCR4 axis might play an important biological role in pituitary adenoma as potential growth and angiogenic factor for pituitary cells. The increased CXCR4 activation may result from either endocrine (increased CXCL12 levels may reach pituitary through the blood stream or being released in the portal pituitary system from hypothalamus) and/or autocrine/paracrine mechanisms (Figure 2). Importantly, the latter mechanism seems to be active mainly in pituitary tumors rather than in normal gland, where most of the CXCR4-expressing normal cells do not express CXCL12 [129].

8. Conclusions

Chemokines are key factors in CNS physiology and pathology, being relevant mediators in cancer development. The CXCL12/CXCR4-R7 signaling pathway plays a unique role in the regulation of a variety of cell types, including embryonic and cancer cells. In particular, deregulation of this chemokinergic system is strictly related to tumor initiation and progression, and the balance of its activity within the tumor microenvironment is highly complex phenomenon.

Multiple factors cooperate to pituitary tumor pathogenesis, but, although to date not explored in depth, a pivotal role of CK and their receptors seems to be important. Several mechanisms by which CXCL12/CXCR4 modulates pituitary function and promotes adenoma cell proliferation and their target as potential therapeutic approach have been suggested. CXCL12 is overexpressed in pituitary cells where it can directly influence adenoma formation, through autocrine mechanisms resulting in constitutive CXCR4 activation. This pathway grants pituitary cells with a proliferative advantage that triggers clonal expansion of transformed cells and sustains tumor cell survival. Increasing knowledge about pituitary cell origin and development might provide significant insights into deregulated pathways in pituitary tumorigenesis.

Finally, CXCR4 is an easily druggable target and the characterization of its role in pituitary adenomas could pave the way for novel pharmacological approaches, especially for those adenoma subtypes, (i.e., TSH and ACTH secreting tumors, as well as NFPA) still waiting for efficacious drugs.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This work was supported by grants from Italian Association for Cancer Research (AIRC) to Federica Barbieri and Tullio Florio.


[1] X. Blanchet, M. Langer, C. Weber, R. Koenen, and P. von Hundelshausen, "Touch of chemokines," Frontiers in Immunology, vol. 3, article 175, 2012.

[2] B. M. L. Verburg-van Kemenade, L. M. van der Aa, and M. Chadzinska, "Neuroendocrine-immune interaction: regulation of inflammation via G-protein coupled receptors," General and Comparative Endocrinology, vol. 188, pp. 94-101, 2012.

[3] A. Bajetto, R. Bonavia, S. Barbero, T. Florio, and G. Schettini, "Chemokines and their receptors in the central nervous system," Frontiers in Neuroendocrinology, vol. 22, no. 3, pp. 147-184, 2001.

[4] A. Zlotnik, O. Yoshie, and H. Nomiyama, "The chemokine and chemokine receptor superfamilies and their molecular evolution," Genome Biology, vol. 7, no. 12, article 243, 2006.

[5] J. L. Williams, D. W. Holman, and R. S. Kein, "Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers," Frontiers in Cellular Neuroscience, vol. 8, article 154, 2014

[6] W. Rostene, A. Guyon, L. Kular et al., "Chemokines and chemokine receptors: new actors in neuroendocrine regulations," Frontiers in Neuroendocrinology, vol. 32, no. 1, pp. 10-24, 2011.

[7] W. Rostene, P. Kitabgi, and S. M. Parsadaniantz, "Chemokines: a new class of neuromodulator?" Nature Reviews Neuroscience, vol. 8, no. 11, pp. 895-904, 2007.

[8] A. Guyon, "CXCL12 chemokine and GABA neurotransmitter systems crosstalk and their putative roles," Frontiers in Cellular Neuroscience, vol. 5, article 115, 2014.

[9] J. Vandercappellen, J. van Damme, and S. Struyf, "The role of CXC chemokines and their receptors in cancer," Cancer Letters, vol. 267, no. 2, pp. 226-244, 2008.

[10] A. Zlotnik, "Chemokines and cancer," International Journal of Cancer, vol. 119, no. 9, pp. 2026-2029, 2006.

[11] U. M. Domanska, R. C. Kruizinga, W. B. Nagengast et al., "A review on CXCR4/CXCL12 axis in oncology: no place to hide," European Journal of Cancer, vol. 49, no. 1, pp. 219-230, 2013.

[12] B. A. Teicher and S. P. Fricker, "CXCL12 (SDF-1)/CXCR4 pathway in cancer," Clinical Cancer Research, vol. 16, no. 11, pp. 2927-2931, 2010.

[13] R. Wurth, A. Bajetto, J. K. Harrison, F. Barbieri, and T. Florio, "CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment," Frontiers in Cellular Neuroscience, vol. 8, article 144, 2014.

[14] S. Melmed, "Pathogenesis of pituitary tumors," Nature Reviews Endocrinology, vol. 7, no. 5, pp. 257-266, 2011.

[15] G. U. Mehta and J. A. Jane, "Pituitarytumors," Current Opinion in Neurology, vol. 25, no. 6, pp. 751-755, 2012.

[16] G. Kontogeorgos, "Classification and pathology of pituitary tumors," Endocrine, vol. 28, no. 1, pp. 27-35, 2005.

[17] G. Kontogeorgos, "Innovations and controversies in the WHO classification of pituitary adenomas," Acta Neuropathologica, vol. 111, no. 1, pp. 73-75, 2006.

[18] S. J. Allen, S. E. Crown, and T. M. Handel, "Chemokine: receptor structure, interactions, and antagonism," Annual Review of Immunology, vol. 25, pp. 787-820, 2007

[19] F. Bachelerie, G. J. Graham, M. Locati et al., "New nomenclature for atypical chemokine receptors," Nature Immunology, vol. 15, no. 3, pp. 207-208, 2014.

[20] S. Rajagopal, J. Kim, S. Ahn et al., "[beta]-arrestin-but not G protein-mediated signaling by the "decoy" receptor CXCR7," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 628-632, 2010.

[21] M. O'Hayre, C. L. Salanga, T. M. Handel, and S. J. Allen, "Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment," Biochemical Journal, vol. 409, no. 3, pp. 635-649, 2008.

[22] G. J. Graham, M. Locati, A. Mantovani, A. Rot, and M. Thelen, "The biochemistry and biology of the atypical chemokine receptors," Immunology Letters, vol. 145, no. 1-2, pp. 30-38, 2012.

[23] F. Bachelerie, A. Ben-Baruch, A. M. Burkhardt et al., "International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors," Pharmacological Reviews, vol. 66, no. 1, pp. 1-79, 2014.

[24] R. M. Strieter, J. A. Belperio, R. J. Phillips, and M. P. Keane, "CXC chemokines in angiogenesis of cancer," Seminars in Cancer Biology, vol. 14, no. 3, pp. 195-200, 2004.

[25] M. Li and R. M. Ransohoff, "The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis," Seminars in Cancer Biology, vol. 19, no. 2, pp. 111-115, 2009.

[26] V. Hannelien, G. Karel, V. D. Jo, and S. Sofie, "The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer," Biochimica et Biophysica Acta, vol. 1825, no. 1, pp. 117-129, 2012.

[27] A. Steen, O. Larsen, S. Thiele et al., "Biased and G protein-independent signaling of chemokine receptors," Frontiers in Immunology, vol. 5, article 277, 2014.

[28] F. Balkwill, "The significance of cancer cell expression of the chemokine receptor CXCR4," Seminars in Cancer Biology, vol. 14, no. 3, pp. 171-179, 2004.

[29] L. M. Luttrell and D. Gesty-Palmer, "Beyond desensitization: physiological relevance of arrestin-dependent signaling," Pharmacological Reviews, vol. 62, no. 2, pp. 305-330, 2010.

[30] A. Viola and A. D. Luster, "Chemokines and their receptors: drug targets in immunity and inflammation," Annual Review of Pharmacology and Toxicology, vol. 48, pp. 171-197, 2008.

[31] J. R. Groom and A. D. Luster, "CXCR3 in T cell function," Experimental Cell Research, vol. 317, no. 5, pp. 620-631, 2011.

[32] A. Bajetto, R. Bonavia, S. Barbero, T. Florio, A. Costa, and G. Schettini, "Expression of chemokine receptors in the rat brain," Annals of the New York Academy of Sciences, vol. 876, pp. 201-209, 1999.

[33] A. Bajetto, R. Bonavia, S. Barbero et al., "Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1," Journal of Neurochemistry, vol. 73, no. 6, pp. 2348-2357, 1999.

[34] G. Banisadr, R.-D. Gosselin, P. Mechighel, P. Kitabgi, W. Rostene, and S. M. Parsadaniantz, "Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides," Journal of Comparative Neurology, vol. 489, no. 3, pp. 275-292, 2005.

[35] Q. Ma, D. Jones, P. R. Borghesani et al., "Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9448-9453, 1998.

[36] Y.-R. Zou, A. H. Kottman, M. Kuroda, I. Taniuchi, and D. R. Littman, "Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development," Nature, vol. 393, no. 6685, pp. 595-599, 1998.

[37] Y. Zhu, T. Matsumoto, S. Mikami, T. Nagasawa, and F. Murakami, "SDF1/CXCR4 signalling regulates two distinct processes of precerebellar neuronal migration and its depletion leads to abnormal pontine nuclei formation," Development, vol. 136, no. 11, pp. 1919-1928, 2009.

[38] Y. Zhu and F. Murakami, "Chemokine CXCL12 and its receptors in the developing central nervous system: emerging themes and future perspectives," Developmental Neurobiology, vol. 72, no. 10, pp. 1349-1362, 2012.

[39] C. Callewaere, G. Banisadr, M. G. Desarmenien et al., "The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopression neurons and counteracts induced vasopressin release through CXCR," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 21, pp. 8221-8226, 2006.

[40] M. Li and R. M. Ransohoff, "Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology," Progress in Neurobiology, vol. 84, no. 2, pp. 116-131, 2008.

[41] W. Rostene, M.-A. Dansereau, D. Godefroy et al., "Neurochemokines: a menage a trois providing new insights on the functions of chemokines

in the central nervous system," Journal of Neurochemistry, vol. 118, no. 5, pp. 680-694, 2011.

[42] A. Bagri, T. Gurney, X. He et al., "The chemokine SDF1 regulates migration of dentate granule cells," Development, vol. 129, no. 18, pp. 4249-4260, 2002.

[43] A. Belmadani, P. B. Tran, D. Ren, S. Assimacopoulos, E. A. Grove, and R. J. Miller, "The chemokine stromal cell-derived factor-1 regulates the migration of sensory neuron progenitors," Journal of Neuroscience, vol. 25, no. 16, pp. 3995-4003, 2005.

[44] V. Borrell and O. Marin, "Meninges control tangential migration of hem-derived Cajal-Retzius cells via CXCL12/CXCR4 signaling," Nature Neuroscience, vol. 9, no. 10, pp. 1284-1293, 2006

[45] M. F. Paredes, G. Li, O. Berger, S. C. Baraban, and S. J. Pleasure, "Stromal-derived factor-1 (CXCL12) regulates laminar position of Cajal-Retzius cells in normal and dysplastic brains," Journal of Neuroscience, vol. 26, no. 37, pp. 9404-9412, 2006.

[46] T. O. Vilz, B. Moepps, J. Engele, S. Molly, D. R. Littman, and K. Schilling, "The SDF-1/CXCR4 pathway and the development of the cerebellar system," European Journal of Neuroscience, vol. 22, no. 8, pp. 1831-1839, 2005.

[47] G. Lopez-Bendito, J. A. Sanchez-Alcaniz, R. Pla et al., "Chemokine signaling controls intracortical migration and final distribution of GABAergic interneurons," Journal of Neuroscience, vol. 28, no. 7, pp. 1613-1624, 2008.

[48] D. E. Lysko, M. Putt, and J. A. Golden, "SDF1 regulates leading process branching and speed of migrating interneurons," The Journal of Neuroscience, vol. 31, no. 5, pp. 1739-1745, 2011.

[49] R. K. Stumm, C. Zhou, T. Ara et al., "CXCR4 regulates interneuron migration in the developing neocortex," Journal of Neuroscience, vol. 23, no. 12, pp. 5123-5130, 2003.

[50] S. Yang, L. C. Edman, J. A. Sanchez-Alcaniz et al., "Cxcl12/Cxcr4 signaling controls the migration and process orientation of A9-A10 dopaminergic neurons," Development (Cambridge), vol. 140, no. 22, pp. 4554-4564, 2013.

[51] R. N. Kaplan, B. Psaila, and D. Lyden, "Niche-to-niche migration of bone-marrow-derived cells," Trends in Molecular Medicine, vol. 13, no. 2, pp. 72-81, 2007

[52] J. M. Burns, B. C. Summers, Y. Wang et al., "A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development," The Journal of Experimental Medicine, vol. 203, no. 9, pp. 2201-2213, 2006.

[53] L. Sanchez-Martin, P. Sanchez-Mateos, and C. Cabanas, "CXCR7 impact on CXCL12 biology and disease," Trends in Molecular Medicine, vol. 19, no. 1, pp. 12-22, 2013.

[54] B. Boldajipour, H. Mahabaleshwar, E. Kardash et al., "Control of chemokine-guided cell migration by ligand sequestration," Cell, vol. 132, no. 3, pp. 463-473, 2008.

[55] K. E. Luker, J. M. Steele, L. A. Mihalko, P. Ray, and G. D. Luker, "Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands," Oncogene, vol. 29, no. 32, pp. 4599-4610, 2010.

[56] U. Naumann, E. Cameroni, M. Pruenster et al., "CXCR7 functions as a scavenger for CXCL12 and CXCL11," PLoS ONE, vol. 5, no. 2, Article ID e9175, 2010.

[57] F. Hoffmann, W. Muller, D. Schutz et al., "Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues," The Journal of Biological Chemistry, vol. 287, no. 34, pp. 28362-28377, 2012.

[58] K. Balabanian, B. Lagane, S. Infantino et al., "The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes," The Journal of Biological Chemistry, vol. 280, no. 42, pp. 35760-35766, 2005.

[59] A. Levoye, K. Balabanian, F. Baleux, F. Bachelerie, and B. Lagane, "CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling," Blood, vol. 113, no. 24, pp. 6085-6093, 2009.

[60] B. A. Zabel, Y. Wang, S. Lewen et al., "Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands," Journal of Immunology, vol. 183, no. 5, pp. 3204-3211, 2009.

[61] K. Grymula, M. Tarnowski, M. Wysoczynski et al., "Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas," International Journal of Cancer, vol. 127, no. 11, pp. 2554-2568, 2010.

[62] K. Hattermann, J. Held-Feindt, R. Lucius et al., "The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects," Cancer Research, vol. 70, no. 8, pp. 3299-3308, 2010.

[63] V. Odemis, K. Boosmann, A. Heinen, P. Kury, and J. Engele, "CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells," Journal of Cell Science, vol. 123, no. 7, pp. 1081-1088, 2010.

[64] J. Wang, Y. Shiozawa, Y. Wang et al., "The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer," The Journal of Biological Chemistry, vol. 283, no. 7, pp. 4283-4294, 2008.

[65] K. Xiao, J. Sun, J. Kim et al., "Global phosphorylation analysis of [beta]-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR)," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 34, pp. 15299-15304, 2010.

[66] F. M. Decaillot, M. A. Kazmi, Y. Lin, S. Ray-Saha, T. P. Sakmar, and P. Sachdev, "CXCR7/CXCR4 heterodimer constitutively recruits [beta]-arrestin to enhance cell migration," The Journal of Biological Chemistry, vol. 286, no. 37, pp. 32188-32197, 2011.

[67] F. Sierro, C. Biben, L. Martinez-Munoz et al., "Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 37, pp. 14759-14764, 2007.

[68] A. K. Singh, R. K. Arya, A. K. Trivedi et al., "Chemokine receptortrio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12," Cytokine and Growth Factor Reviews, vol. 24, no. 1, pp. 41-49, 2013.

[69] Y. Wang, G. Li, A. Stanco et al., "CXCR4 and CXCR7 have distinct functions in regulating interneuron migration," Neuron, vol. 69, no. 1, pp. 61-76, 2011.

[70] L. J. Drurya, J. J. Ziarek, S. Gravel et al., "Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 43, pp. 17655-17660, 2011.

[71] P. Ray, L. A. Mihalko, N. L. Coggins et al., "Carboxy-terminus of CXCR7 regulates receptor localization and function," International Journal of Biochemistry and Cell Biology, vol. 44, no. 4, pp. 669-678, 2012.

[72] C. Ierano, S. Santagata, M. Napolitano et al., "CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells," Cell Death & Disease, vol. 5, Article ID e1310, 2014.

[73] H. Gerrits, D. S. Van Ingen Schenau, N. E. C. Bakker et al., "Early postnatal lethality and cardiovascular defects in CXCR7-deficient mice," Genesis, vol. 46, no. 5, pp. 235-245, 2008.

[74] K. E. Luker, M. Gupta, J. M. Steele, B. R. Foerster, and G. D. Luker, "Imaging ligand-dependent activation of CXCR7," Neoplasia, vol. 11, no. 10, pp. 1022-1035, 2009.

[75] B. Schonemeier, A. Kolodziej, S. Schulz, S. Jacobs, V. Hoellt, and R. Stumm, "Regional and cellular localization of the CXC112/SDF-1 chemokine receptor CXCR7 in the developing and adult rat brain," Journal of Comparative Neurology, vol. 510, no. 2, pp. 207-220, 2008.

[76] M. Thelen and S. Thelen, "CXCR7, CXCR4 and CXCL12: an eccentric trio?" Journal of Neuroimmunology, vol. 198, no. 1-2, pp. 9-13, 2008.

[77] J. A. Sanchez-Alcaniz, S. Haege, W. Mueller et al., "Cxcr7 controls neuronal migration by regulating chemokine responsiveness," Neuron, vol. 69, no. 1, pp. 77-90, 2011.

[78] D. Virgintino, M. Errede, M. Rizzi et al., "The CXCL12/ CXCR4/CXCR7 ligand-receptor system regulates neuro-gliovascular interactions and vessel growth during human brain development," Journal of Inherited Metabolic Disease, vol. 36, no. 3, pp. 455-466, 2013.

[79] L. Cruz-Orengo, D. W. Holman, D. Dorsey et al., "CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity," The Journal of Experimental Medicine, vol. 208, no. 2, pp. 327-339, 2011.

[80] Y. M. Li, Y. Pan, Y. Wei et al., "Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis," Cancer Cell, vol. 6, no. 5, pp. 459-469, 2004.

[81] P. Abe, W. Mueller, D. Schutz et al., "CXCR7 prevents excessive CXCL12-mediated downregulation of CXCR4 in migrating cortical interneurons," Development, vol. 141, no. 9, pp. 1857-1863, 2014.

[82] F. Casoni, I. Hutchins, D. Donohue, M. Fornaro, B. G. Condie, and S. Wray, "SDF and GABA interact to regulate axophilic migration of GnRH neurons," Journal of Cell Science, vol. 125, part 21, pp. 5015-5025, 2012.

[83] F. Memi, P. Abe, A. Cariboni, F. MacKay, J. G. Parnavelas, and R. Stumm, "CXC chemokine receptor 7 (CXCR7) affects the migration of GnRH neurons by regulating CXCL12 availability," Journal of Neuroscience, vol. 33, no. 44, pp. 17527-17537, 2013.

[84] T. Florio, "Adult pituitary stem cells: from pituitary plasticity to adenoma development," Neuroendocrinology, vol. 94, no. 4, pp. 265-277, 2011.

[85] M. Garcia-Lavandeira, V. Quereda, I. Flores et al., "A GRFa2/Prop1/Stem (GPS) cell niche in the pituitary," PLoS ONE, vol. 4, no. 3, Article ID e4815, 2009.

[86] K. Horiguchi, C. Ilmiawati, K. Fujiwara, T. Tsukada, M. Kikuchi, and T. Yashiro, "Expression of chemokine CXCL12 and its receptor CXCR4 in folliculostellate (FS) cells of the rat anterior pituitary gland: the CXCL12/CXCR4 axis induces interconnection of FS cells," Endocrinology, vol. 153, no. 4, pp. 1717-1724, 2012

[87] H. Vankelecom, "Stem cells in the postnatal pituitary?" Neuroendocrinology, vol. 85, no. 2, pp. 110-130, 2007

[88] H. Vankelecom, "Non-hormonal cell types in the pituitary candidating for stem cell," Seminars in Cell and Developmental Biology, vol. 18, no. 4, pp. 559-570, 2007.

[89] O. Krylyshkina, J. Chen, L. Mebis, C. Denef, and H. Vankelecom, "Nestin-immunoreactive cells in rat pituitary are neither hormonal nor typical folliculo-stellate cells," Endocrinology, vol. 146, no. 5, pp. 2376-2387, 2005.

[90] H. Vankelecom and L. Gremeaux, "Stem cells in the pituitary gland: a burgeoning field," General and Comparative Endocrinology, vol. 166, no. 3, pp. 478-488, 2010.

[91] H. Vankelecom and J. Chen, "Pituitary stem cells: where do we stand?" Molecular and Cellular Endocrinology, vol. 385, no. 1-2, pp. 2-17, 2014.

[92] T. Florio and F. Barbieri, "The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells," Drug Discovery Today, vol. 17, no. 19-20, pp. 1103-1110, 2012.

[93] M. Gatti, A. Pattarozzi, A. Bajetto et al., "Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity," Toxicology, vol. 314, no. 2-3, pp. 209-220, 2013.

[94] C. Denef, "Paracrinicity: the story of 30 years of cellular pituitary crosstalk," Journal of Neuroendocrinology, vol. 20, no. 1, pp. 1-70, 2008.

[95] F. Barbieri, A. Bajetto, C. Porcille, A. Pattarozzi, G. Schettini, and T. Florio, "Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function," Journal of Molecular Endocrinology, vol. 38, no. 3-4, pp. 383-389, 2007

[96] M. Fuertes, J. Gerez, M. Haedo et al., "Cytokines and genes in pituitary tumorigenesis: RSUME role in cell biology," Frontiers of Hormone Research, vol. 38, pp. 1-6, 2010.

[97] M. R. Haedo, J. Gerez, M. Fuertes et al., "Regulation of pituitary function by cytokines," Hormone Research, vol. 72, no. 5, pp. 266-274, 2009.

[98] O. Cooper, G. Vlotides, H. Fukuoka, M. I. Greene, and S. Melmed, "Expression and function of ErbB receptors and ligands in the pituitary," Endocrine-Related Cancer, vol. 18, no. 6, pp. R197-R211, 2011.

[99] E. T. Cunningham Jr., E. Wada, D. B. Carter, D. E. Tracey, J. F. Battey, and E. B. De Souza, "In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse," Journal of Neuroscience, vol. 12, no. 3, pp. 1101-1114, 1992.

[100] G. Schettini, T. Florio, O. Meucci et al., "Interleukin-1-[beta] modulation of prolactin secretion from rat anterior pituitary cells: involvement of adenylate cyclase activity and calcium mobilization," Endocrinology, vol. 126, no. 3, pp. 1435-1441, 1990.

[101] G. Schettini, T. Florio, O. Meucci, G. Scala, E. Landolfi, and M. Grimaldi, "Effect of interleukin 1 beta on transducing mechanisms in 235-1 clonal pituitary cells. Part I: modulation of adenylate cyclase activity," Biochemical and Biophysical Research Communications, vol. 155, no. 3, pp. 1089-1096, 1988.

[102] G. Schettini, O. Meucci, T. Florio, G. Scala, E. Landolfi, and M. Grimaldi, "Effect of interleukin 1 beta on transducing mechanisms in 235-1 clonal pituitary cells. Part II: modulation of calcium fluxes," Biochemical and Biophysical Research Communications, vol. 155, no. 3, pp. 1097-1104, 1988.

[103] G. Schettini, E. Landolfi, M. Grimaldi et al., "Interleukin 1 beta inhibition of TRH-stimulated prolactin secretion and phosphoinositides metabolism," Biochemical and Biophysical Research Communications, vol. 165, no. 1, pp. 496-505, 1989.

[104] A. Hanisch, K. D. Dieterich, K. Dietzmann et al., "Expression of members of the interleukin-6 family of cytokines and their receptors in human pituitary and pituitary adenomas," The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 11, pp. 4411-4414, 2000.

[105] J. A. Moro, J. Carretero, M. I. Alonso, C. Martin, A. Gato, and A. D. L. Mano, "Prenatal expression of interleukin 1[beta] and interleukin 6 in the rat pituitary gland," Cytokine, vol. 44, no. 3, pp. 315-322, 2008.

[106] J. Carretero, G. Vazquez, E. Blanco et al., "Immunohistochemical evidence of the presence of aromatase P450 in the rat hypophysis," Cell and Tissue Research, vol. 295, no. 3, pp. 419-423, 1999.

[107] U. Renner, J. Gloddek, E. Arzt, K. Inoue, and G. K. Stalla, "Interleukin-6 is an autocrine growth factor for folliculostellate-like TtT/GF mouse pituitary tumor cells," Experimental and Clinical Endocrinology and Diabetes, vol. 105, no. 6, pp. 345-352, 1997

[108] M. Higuchi, S. Yoshida, H. Ueharu, M. Chen, T. Kato, and Y. Kato, "PRRX1 and PRRX2 distinctively participate in pituitary organogenesis and a cell-supply system," Cell and Tissue Research, vol. 357, no. 1, pp. 323-335, 2014.

[109] M. Paez Pereda, P. Lohrer, D. Kovalovsky et al., "Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas," Experimental and Clinical Endocrinology and Diabetes, vol. 108, no. 3, pp. 202-207, 2000.

[110] G. Schettini, M. Grimaldi, E. Landolfi et al., "Role of interleukin-6 in the neuroendocrine system," Acta Neurologica, vol. 13, no. 4, pp. 361-367, 1991.

[111] B. L. Spangelo, A. M. Judd, P. C. Isakson, and R. M. MacLeod, "Interleukin-6 stimulates anterior pituitary hormone release in vitro," Endocrinology, vol. 125, no. 1, pp. 575-577, 1989.

[112] T. Florio, E. Landolfi, M. Grimaldi et al., "Interleukin-6 mediates neural-immune interactions: study on prolactin release and intracellular transducing mechanisms," Pharmacological Research, vol. 22, supplement 3, article 54, 1990.

[113] M. Grimaldi, O. Meucci, A. Scorziello et al., "Interleukin 6 modulation of second messenger systems in anterior pituitary cells," Life Sciences, vol. 51, no. 16, pp. 1243-1248, 1992.

[114] E. Arzt, R. Buric, G. Stelzer et al., "Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6," Endocrinology, vol. 132, no. 1, pp. 459-467, 1993.

[115] Y. Nagai, K. Watanabe, H. Aso, S. Ohwada, Y. Muneta, and T. Yamaguchi, "Cellular localization of IL-18 and IL-18 receptor in pig anterior pituitary gland," Domestic Animal Endocrinology, vol. 30, no. 2, pp. 144-154, 2006.

[116] E. J. Blanco, M. Carretero-Hernandez, J. Garcia-Barrado et al., "The activity and proliferation of pituitary prolactin-positive cells and pituitary VIP-positive cells are regulated by interleukin 6," Histology and Histopathology, vol. 28, no. 12, pp. 1595-1604, 2013

[117] Y. Sakamoto, K. Koike, H. Kiyama et al., "Endotoxin activates a chemokinergic neuronal pathway in the hypothalamo- pituitary system," Endocrinology, vol. 137, no. 10, pp. 4503-4506, 1996.

[118] T. Sawada, K. Koike, Y. Kanda et al., "In vitro effects of CINC/gro, a member of the interleukin-8 family, on hormone secretion by rat anterior pituitary cells," Biochemical and Biophysical Research Communications, vol. 202, no. 1, pp. 155-160, 1994

[119] C. Callewaere, G. Banisadr, W. Rostene, and S. M. Parsadaniantz, "Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation," Journal of Molecular Endocrinology, vol. 38, no. 3, pp. 355-363, 2007

[120] E. Itakura, K. Odaira, K. Yokoyama, M. Osuna, T. Hara, and K. Inoue, "Generation of transgenic rats expressing green fluorescent protein in s-100[beta]-producing pituitary folliculostellate cells and brain astrocytes," Endocrinology, vol. 148, no. 4, pp. 1518-1523, 2007.

[121] K. Horiguchi, M. Kikuchi, K. Kusumoto et al., "Living-cell imaging of transgenic rat anterior pituitary cells in primary culture reveals novel characteristics of folliculo-stellate cells," Journal of Endocrinology, vol. 204, no. 2, pp. 115-123, 2010.

[122] K. Horiguchi, K. Fujiwara, M. Higuchi et al., "Expression of chemokine CXCL10 in dendritic-cell-like S100[beta]-positive cells in rat anterior pituitary gland," Cell and Tissue Research, vol. 357, no. 3, pp. 757-765, 2014.

[123] G. Banisadr, E. Dicou, T. Berbar, W. Rostene, A. Lombet, and F. Haour, "Characterization and visualization of [[sup.125]I] stromal cell-derived factor-1a binding to CXCR4 receptors in rat brain and human neuroblastoma cells," Journal of Neuroimmunology, vol. 110, no. 1-2, pp. 151-160, 2000.

[124] G. Banisadr, P. Fontanges, F. Haour, P. Kitabgi, W. Rostene, and S. M. Parsadaniantz, "Neuroanatomical distribution of CXCR4 in adult rat brain and its localization in cholinergic and dopaminergic neurons," European Journal of Neuroscience, vol. 16, no. 9, pp. 1661-1671, 2002.

[125] G. Banisadr, D. Skrzydelski, P. Kitabgi, W. Rostene, and S. Melik Parsadaniantz, "Highly regionalized distribution of stromal cellderived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons," European Journal of Neuroscience, vol. 18, no. 6, pp. 1593-1606, 2003.

[126] C. Callewaere, B. Fernette, D. Raison et al., "Cellular and subcellular evidence for neuronal interaction between the chemokine stromal cell-derived factor-1/CXCL 12 and vasopressin: regulation in the hypothalamo-neurohypophysial system of the Brattleboro rats," Endocrinology, vol. 149, no. 1, pp. 310-319, 2008

[127] T. Florio, S. Casagrande, F. Diana et al., "Chemokine stromal cell-derived factor 1a induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals," Molecular Pharmacology, vol. 69, no. 2, pp. 539-546, 2006.

[128] Y. Lee, J. M. Kim, and E. J. Lee, "Functional expression of CXCR4 in somatotrophs: CXCL12 activates GH gene, GH production and secretion, and cellular proliferation," Journal of Endocrinology, vol. 199, no. 2, pp. 191-199, 2008.

[129] F. Barbieri, A. Bajetto, R. Stumm et al., "Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas," Clinical Cancer Research, vol. 14, no. 16, pp. 5022-5032, 2008

[130] T. Tang, Q.-J. Xia, J.-B. Chen, M.-R. Xi, and D. Lei, "Expression of the CXCL12/SDF-1 chemokine receptor CXCR7 in human brain tumours," Asian Pacific Journal of Cancer Prevention, vol. 13, no. 10, pp. 5281-5286, 2012.

[131] D. Yoshida, R. Nomura, and A. Teramoto, "Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1a, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells," Journal of Neuroendocrinology, vol. 21, no. 5, pp. 481-488, 2009.

[132] N. Cabioglu, J. Summy, C. Miller et al., "CXCL-12/stromal cell-derived factor-1a transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation," Cancer Research, vol. 65, no. 15, pp. 6493-6497, 2005.

[133] A. Pattarozzi, M. Gatti, F. Barbieri et al., "17[beta]-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment," Molecular Pharmacology, vol. 73, no. 1, pp. 191-202, 2008.

[134] C. Porcile, A. Bajetto, F. Barbieri et al., "Stromal cell-derived factor-1a (SDF-1a/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation," Experimental Cell Research, vol. 308, no. 2, pp. 241-253, 2005.

[135] C. A. Del Vecchio, C. P. Giacomini, H. Vogel et al., "EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms," Oncogene, vol. 32, no. 21, pp. 2670-2681, 2013

[136] M. Rahimi, J. George, and C. Tang, "EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms," International Journal of Cancer, vol. 126, no. 8, pp. 1850-1860, 2010.

[137] R. D. Chernock, R. P. Cherla, and R. K. Ganju, "SHP2 and cb1 participate in a-chemokine receptor CXCR4-mediated signaling pathways," Blood, vol. 97, no. 3, pp. 608-615, 2001.

[138] C. M. Wain, J. Westwick, and S. G. Ward, "Heterologous regulation of chemokine receptor signaling by the lipid phosphatase SHIP in lymphocytes," Cellular Signalling, vol. 17, no. 10, pp. 1194-1202, 2005.

[139] T. Florio, "Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases," Molecular and Cellular Endocrinology, vol. 286, no. 1-2, pp. 40-48, 2008.

[140] T. Florio, S. Arena, S. Thellung et al., "The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation," Journal of MolecularEndocrinology,vol. 15, no. 10, pp. 1838-1852, 2001

[141] M. G. Pan, T. Florio, and P J. S. Stork, "G protein activation of a hormone-stimulated phosphatase in human tumor cells," Science, vol. 256, no. 5060, pp. 1215-1217, 1992.

[142] T. Florio, "Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors," Frontiers in Bioscience, vol. 13, no. 3, pp. 822-840, 2008.

[143] F. Barbieri, A. Bajetto, A. Pattarozzi et al., "Peptide receptor targeting in cancer: the somatostatin paradigm," International Journal of Peptides, vol. 2013, Article ID 926295, 20 pages, 2013.

[144] H. Kang, G. Watkins, C. Parr, A. Douglas-Jones, R. E. Mansel, and W. G. Jiang, "Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer," Breast Cancer Research, vol. 7, no. 4, pp. R402-R410, 2005

[145] S. A. Rempel, S. Dudas, S. Ge, and J. A. Gutierrez, "Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma," Clinical Cancer Research, vol. 6, no. 1, pp. 102-111, 2000.

[146] M. Thelen and J. V. Stein, "How chemokines invite leukocytes to dance," Nature Immunology, vol. 9, no. 9, pp. 953-959, 2008.

[147] A. Bajetto, F. Barbieri, A. Dorcaratto et al., "Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration," Neurochemistry International, vol. 49, no. 5, pp. 423-432, 2006.

[148] S. Barbero, R. Bonavia, A. Bajetto et al., "Stromal cell-derived factor 1a stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt," Cancer Research, vol. 63, no. 8, pp. 1969-1974, 2003.

[149] J. B. Rubin, A. L. Kung, R. S. Klein et al., "A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13513-13518, 2003

[150] A. Bajetto, F. Barbieri, A. Pattarozzi et al., "CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro," Neuro-Oncology, vol. 9, no. 1, pp. 3-11, 2007.

[151] F. Barbieri, A. Bajetto, C. Porcile et al., "CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation," Annals of the New York Academy of Sciences, vol. 1090, pp. 332-343, 2006.

[152] R. Wurth, F. Barbieri, A. Bajetto et al., "Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature," Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 115-123, 2011.

[153] K. E. Luker and G. D. Luker, "Functions of CXCL12 and CXCR4 in breast cancer," Cancer Letters, vol. 238, no. 1, pp. 30-41, 2006.

[154] J. M. Hall and K. S. Korach, "Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells," Molecular Endocrinology, vol. 17, no. 5, pp. 792-803, 2003.

[155] A. Muller, B. Homey, H. Soto et al., "Involvement of chemokine receptors in breast cancer metastasis," Nature, vol. 410, no. 6824, pp. 50-56, 2001.

[156] C. J. Scotton, J. L. Wilson, D. Milliken, G. Stamp, and F. R. Balkwill, "Epithelial cancer cell migration: a role for chemokine receptors?" Cancer Research, vol. 61, no. 13, pp. 4961-4965, 2001.

[157] N. Mukaida and T. Baba, "Chemokines in tumor development and progression," Experimental Cell Research, vol. 318, no. 2, pp. 95-102, 2012.

[158] M. Cojoc, C. Peitzsch, F. Trautmann, L. Polishchuk, G. D. Telegeev, and A. Dubrovska, "Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis," OncoTargets and Therapy, vol. 6, pp. 1347-1361, 2013.

[159] A. Ferrari, C. Petterino, A. Ratto et al., "CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis," BMC Veterinary Research, vol. 8, article 27, 2012.

[160] V. Mirisola, A. Zuccarino, B. E. Bachmeier et al., "CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival," European Journal of Cancer, vol. 45, no. 14, pp. 2579-2587, 2009.

[161] M. Arya, H. R. H. Patel, C. McGurk et al., "The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis," Journal of Experimental Therapeutics and Oncology, vol. 4, no. 4, pp. 291-303, 2004.

[162] I. S. Zeelenberg, L. Ruuls-Van Stalle, and E. Roos, "The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases," Cancer Research, vol. 63, no. 13, pp. 3833-3839, 2003.

[163] F. Barbieri, A. Bajetto, and T. Florio, "Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target," Journal of Oncology, Article ID 426956, 2010.

[164] L. Wang, L. Wang, B. Yang et al., "Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis," Clinical and Experimental Metastasis, vol. 26, no. 8, pp. 1049-1054, 2009.

[165] D. Uchida, T. Onoue, Y. Tomizuka et al., "Involvement of an autocrine stromal cell-derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma," Molecular Cancer Research, vol. 5, no. 7, pp. 685-694, 2007

[166] S. Scala, P. Giuliano, P. A. Ascierto et al., "Human melanoma metastases express functional CXCR4," Clinical Cancer Research, vol. 12, no. 8, pp. 2427-2433, 2006.

[167] L. Hernandez, M. A. O. Magalhaes, S. J. Coniglio, J. S. Condeelis, and J. E. Segall, "Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis," Breast Cancer Research, vol. 13, no. 6, article R128, 2011.

[168] M. Cakir and A. B. Grossman, "Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis," Expert Opinion on Therapeutic Targets, vol. 13, no. 9, pp. 1121-1134, 2009.

[169] Z. Suojun, W. Feng, G. Dongsheng, and L. Ting, "Targeting Raf/MEK/ERK pathway in pituitary adenomas," European Journal of Cancer, vol. 48, no. 3, pp. 389-395, 2012.

[170] D. Dworakowska, E. Wlodek, C. A. Leontiou et al., "Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors," Endocrine-Related Cancer, vol. 16, no. 4, pp. 1329-1338, 2009.

[171] D. Kovalovsky, D. Refojo, A. C. Liberman et al., "Activation and induction of Nur77/Nurr1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase a, and MAPK pathways," Molecular Endocrinology, vol. 16, no. 7, pp. 1638-1651, 2002.

[172] S. P Bliss, A. M. Navratil, J. Xie, and M. S. Roberson, "GnRH signaling, the gonadotrope and endocrine control of fertility," Frontiers in Neuroendocrinology, vol. 31, no. 3, pp. 322-340, 2010.

[173] M. Pertuit, D. Romano, C. Zeiiler, A. Barlier, A. Enjalbert, and C. Gerard, "The gsp oncogene disrupts Ras/ERK-dependent prolactin gene regulation in gsp inducible somatotroph cell line," Endocrinology, vol. 152, no. 4, pp. 1234-1243, 2011.

[174] M. Musat, M. Korbonits, B. Kola et al., "Enhanced protein kinase B/Akt signalling in pituitary tumours," Endocrine-Related Cancer, vol. 12, no. 2, pp. 423-433, 2005.

[175] C. Lu, M. C. Willingham, F. Furuya, and S.-Y. Cheng, "Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors," Endocrinology, vol. 149, no. 7, pp. 3339-3345, 2008.

[176] M. Theodoropoulou, G. K. Stalla, and D. Spengler, "ZAC1 target genes and pituitary tumorigenesis," Molecular and Cellular Endocrinology, vol. 326, no. 1-2, pp. 60-65, 2010.

[177] M. Theodoropoulou, J. Zhang, S. Laupheimeret al., "Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression," Cancer Research, vol. 66, no. 3, pp. 1576-1582, 2006.

[178] M. Saraga-Babic, M. Bazina, K. Vukojevic, I. Bocina, and V. Stefanovic, "Involvement of pro-apoptotic and anti-apoptotic factors in the early development of the human pituitary gland," Histology and Histopathology, vol. 23, no. 10, pp. 1259-1268, 2008

[179] N. Kapranos, G. Kontogeorgos, E. Horvath, and K. Kovacs, "Morphology, molecular regulation and significance of apoptosis in pituitary adenomas," Frontiers of Hormone Research, vol. 32, pp. 217-234, 2004.

[180] D. Sambaziotis, N. Kapranos, and G. Kontogeorgos, "Correlation of Bcl-2 and Bax with apoptosis in human pituitary adenomas," Pituitary, vol. 6, no. 3, pp. 127-133, 2003.

[181] G. Jaita, S. Zarate, L. Ferrari et al., "Gonadal steroids modulate Fas-induced apoptosis of lactotropes and somatotropes," Endocrine, vol. 39, no. 1, pp. 21-27, 2011.

[182] L. Chen, G. Zhuang, W. Li, Y. Liu, J. Zhang, and X. Tian, "RGD-FasL induces apoptosis of pituitary adenoma cells," Cellular and Molecular Immunology, vol. 5, no. 1, pp. 61-68, 2008.

[183] J. Acunzo, C. Roche, C. Defilles et al., "Inactivation of PITX2 transcription factor induced apoptosis of gonadotroph tumoral cells," Endocrinology, vol. 152, no. 10, pp. 3884-3892, 2011.

[184] E. Diaz-Rodriguez, M. Garcia-Lavandeira, S. Perez-Romero et al., "Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells," Oncogene, vol. 31, no. 23, pp. 2824-2835, 2012.

[185] V. Chesnokova, S. Zonis, A. Ben-Shlomo, K. Wawrowsky, and S. Melmed, "Molecular mechanisms of pituitary adenoma senescence," Frontiers of Hormone Research, vol. 38, pp. 7-14, 2010

[186] A. B. Cohen and S. Lessell, "Angiogenesis and pituitary tumors," Seminars in Ophthalmology, vol. 24, no. 3, pp. 185-189, 2009.

[187] C. B. Pizarro, M. C. Oliveira, J. F. S. Pereira-Lima et al., "Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker," Neuropathology, vol. 29, no. 1, pp. 40-44, 2009

[188] L. D. Ortiz, L. V. Syro, B. W. Scheithauer et al., "Anti-VEGF therapy in pituitary carcinoma," Pituitary, vol. 15, no. 3, pp. 445-449, 2012.

[189] B. Shan, J. Gerez, M. Haedo et al., "RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells," Endocrine-Related Cancer, vol. 19, no. 1, pp. 13-27, 2012.

[190] S. Vidal, E. Horvath, K. Kovacs, T. Kuroki, R. V. Lloyd, and B. W. Scheithauer, "Expression of hypoxia-inducible factor-1[alpha] (HIF-1[alpha]) in pituitary tumours," Histology and Histopathology, vol. 18, no. 3, pp. 679-686, 2003.

[191] Z. Xiao, Q. Liu, B. Zhao, J. Wu, and T. Lei, "Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF1a signaling pathway," Oncology Reports, vol. 26, no. 6, pp. 1457-1464, 2011.

[192] M. Theodoropoulou, "A general overview on pituitary tumorigenesis," Annales d'Endocrinologie, vol. 73, no. 2, pp. 71-72, 2012.

[193] O. Mete, S. Ezzat, and S. L. Asa, "Biomarkers of aggressive pituitary adenomas," Journal of Molecular Endocrinology, vol. 49, no. 2, pp. R69-R78, 2012.

[194] M. A. Tichomirowa, A. Barlier, A. F. Daly et al., "High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas," European Journal of Endocrinology, vol. 165, no. 4, pp. 509-515, 2011

[195] R. V. Thakker, "Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)," Molecular and Cellular Endocrinology, vol. 386, no. 1-2, pp. 2-15, 2014.

[196] A. G. Lania, S. Ferrero, R. Pivonello et al., "Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation," The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 1, pp. 13-17, 2010.

[197] K. J. Dudley, K. Revill, R. N. Clayton, and W. E. Farrell, "Pituitary tumours: all silent on the epigenetics front," Journal of Molecular Endocrinology, vol. 42, no. 6, pp. 461-468, 2009.

[198] M. Sivapragasam, F. Rotondo, R. V Lloyd et al., "MicroRNAs in the human pituitary," Endocrine Pathology, vol. 22, no. 3, pp. 134-143, 2011.

[199] V. L. Green, S. L. Atkin, V Speirs et al., "Cytokine expression in human anterior pituitary adenomas," Clinical Endocrinology, vol. 45, no. 2, pp. 179-185, 1996.

[200] M. E. R. Suliman, J. A. Royds, L. Baxter, W. R. Timperley, D. R. Cullen, and T. H. Jones, "IL-8 mRNA expression by in situ hybridisation in human pituitary adenomas," European Journal of Endocrinology, vol. 140, no. 2, pp. 155-158, 1999.

[201] T. Tecimer, J. Dlott, A. Chuntharapai, A. W. Martin, and S. C. Peiper, "Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells," Archives of Pathology and Laboratory Medicine, vol. 124, no. 4, pp. 520-525, 2000

[202] S. D. Vindelov, M.-L. Hartoft-Nielsen, A. K. Rasmussen et al., "Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1[beta] and inhibited by growth hormone releasing hormone and somatostatin," Growth Hormone & IGF Research, vol. 21, no. 3, pp. 134-139, 2011.

[203] R. Nomura, D. Yoshida, and A. Teramoto, "Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia," Journal of Neuro-Oncology, vol. 94, no. 2, pp. 173-181, 2009.

[204] Y. H. Lee, T. W. Noh, M. K. Lee, J. L. Jameson, and E. J. Lee, "Absence of activating mutations of CXCR4 in pituitary tumours," Clinical Endocrinology, vol. 72, no. 2, pp. 209-213, 2010

[205] F. Barbieri, A. Bajetto, A. Pattarozzi et al., "The chemokine SDF1/CXCL12: a novel autocrine/paracrine factor involved in pituitary adenoma development," The Open Neuroendocrinology Journal, vol. 4, no. 1, pp. 64-76, 2011.

[206] B. Xing, Y. G. Kong, Y. Yao, W. Lian, R. Z. Wang, and Z. Y. Ren, "Study on the expression levels of CXCR4, CXCL12, CD44, and CD147 and their potential correlation with invasive behaviors of pituitary adenomas," Biomedical and Environmental Sciences, vol. 26, no. 7, pp. 592-598, 2013.

[207] J. Kim, H. Takeuchi, S. T. Lam et al., "Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival," Journal of Clinical Oncology, vol. 23, no. 12, pp. 2744-2753, 2005.

[208] P. Viacava, M. Gasperi, G. Acerbi et al., "Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas," Journal of Endocrinological Investigation, vol. 26, no. 1, pp. 23-28, 2003.

[209] S. Yamada and K. Takada, "Angiogenesis in pituitary adenomas," Microscopy Research and Technique, vol. 60, no. 2, pp. 236-243, 2003

[210] D. Yoshida, K. Koketshu, R. Nomura, and A. Teramoto, "The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells," Journal of Neuro-Oncology, vol. 100, no. 1, pp. 51-64, 2010.

[211] A. Massa, S. Casagrande, A. Bajetto et al., "SDF-1 controls pituitary cell proliferation through the activation of ERK1/2 and the [Ca.sup.2+]-dependent, cytosolic tyrosine kinase Pyk2," Annals of the New York Academy of Sciences, vol. 1090, pp. 385-398, 2006.

[212] R. M. Vitale, M. Gatti, M. Carbone et al., "Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine A as a new CXCR4 ligand exhibiting antagonist activity," ACS Chemical Biology, vol. 8, no. 12, pp. 2762-2770, 2013.

[213] J. M. Kim, Y.-H. Lee, C. R. Ku, and E. J. Lee, "The cyclic pentapeptide d-arg3FC131, a CXCR4 antagonist, induces apoptosis of somatotrope tumor and inhibits tumor growth in nude mice," Endocrinology, vol. 152, no. 2, pp. 536-544, 2011.

[214] T. Florio, F. Barbieri, R. Spaziante et al., "Efficacy of a dopaminesomatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study," Endocrine-Related Cancer, vol. 15, no. 2, pp. 583-596, 2008.

Federica Barbieri, Stefano Thellung, Roberto Wurth, Federico Gatto, Alessandro Corsaro, Valentina Villa, Mario Nizzari, Manuela Albertelli, Diego Ferone, and Tullio Florio

Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy

Correspondence should be addressed to Federica Barbieri;

Received 18 July 2014; Accepted 21 October 2014; Published 17 November 2014

Academic Editor: Daizo Yoshida
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Barbieri, Federica; Thellung, Stefano; Wurth, Roberto; Gatto, Federico; Corsaro, Alessandro; Villa,
Publication:International Journal of Endocrinology
Article Type:Report
Geographic Code:4EUIT
Date:Jan 1, 2014
Previous Article:Coordinated actions of FXR and LXR in metabolism: from pathogenesis to pharmacological targets for type 2 diabetes.
Next Article:Coexistence of histologically confirmed Hashimoto's thyroiditis with different stages of papillary thyroid carcinoma in a consecutive Chinese cohort.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |